Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02354638|
Recruitment Status : Completed
First Posted : February 3, 2015
Last Update Posted : April 30, 2018
In addition to the passengers smoking inside the cab, the taxi drivers,are themselves addicted to smoking and/ or use of smokeless tobacco. Since tobacco is highly addictive, the cab drivers using tobacco need help in quitting. It is also necessary to raise the awareness of the cab drivers with respect to the hazards of tobacco and significance of the smoke free legislation.
It's been six years since the implementation of rules prohibiting smoking in public places and a re-look at the compliance to this regulation is necessary. The study will also help tobacco users to quit their habits. They will get screened for oral premalignant and malignant lesions.
Also, the cab drivers may pass on some effective messages regarding importance of keeping oneself away from tobacco, to the customers while commuting. In view of the above background, the current study is proposed to look at all these aspects.
The findings of the study will be certainly generating useful information with regards to lacunae in the existing system for appropriate implementation and for strengthening anti tobacco advocacy in our country.
|Condition or disease||Intervention/treatment||Phase|
|Compliance||Behavioral: Tobacco users Drug: Pharmacotherapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||400 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai, India|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||April 2018|
|Actual Study Completion Date :||April 2018|
Experimental: Tobacco users: behavioural counseling
The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
Behavioral: Tobacco users
Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
Pharmacotherapy will also be prescribed as per the need assessment consisting of:
Nicotine Chewing Gums:
Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months
Nicotine Transdermal patches:
Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks
Other Name: Nicotine replacement therapy
No Intervention: Non Users
The cab drivers who are not using tobacco in any form will not receive any type of intervention
- Knowledge, Attitude & practice (change in the baseline KAP) [ Time Frame: 30 months ]a) The
- Attitude regarding implementation of smoke free policy (perceptions and attitude of cab drivers) [ Time Frame: 30 months ]b) The perceptions and attitude of cab drivers regarding implementation of smoke free cab policy.
- Oral cancer detection by oral screening [ Time Frame: 30 months ]c)The results of oral cancer screening in the form of oral pre-cancers and cancers detected
- Quit rates (self reported quit rates) [ Time Frame: 30 months ]d) The success of tobacco cessation programme in the form of self reported quit rates at the end of one year
- Reactions towards no tobacco messages (Reactions of the commuters and their own perceptions) [ Time Frame: 30 months ]e) Reactions of the commuters and their own perceptions towards the no tobacco messages conveyed to the customers while traveling
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02354638
|Gauravi A. Mishra|
|Mumbai, Maharashtra, India, 400012|
|Principal Investigator:||Gauravi A Mishra, Assoc Prof||Tata Memorial Hospital, Mumbai|
|Principal Investigator:||Sharmila A Pimple, Professor||Tata Memorial Hospital, Mumbai|